There were 358 press releases posted in the last 24 hours and 170,208 in the last 365 days.

IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF BELLICUM PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern…

Lead Plaintiff Deadline is April 9, 2018

/EIN News/ -- NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ:BLCM) and certain of its officers in United States District Court for the Southern District of Texas with a class period between May 8, 2017, and January 30, 2018, both dates inclusive.

Investors who have incurred losses in Bellicum Pharmaceuticals, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares of Bellicum Pharmaceuticals, Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no later than April 9, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Bellicum Pharmaceuticals, Inc.  

Bellicum operates as a clinical stage biopharmaceutical company. The Company focuses on discovering and developing novel cellular immunotherapies for various forms of cancer.

The Company's lead clinical product candidate, BPX-501, is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation.   Bellicum has represented that BPX-501 is currently being evaluated in multiple Phase 1/2 clinical trials.

The filed Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:

  • a substantial undisclosed risk of encephalopathy was associated with the Company's lead product candidate BPX-501; and
     
  • as a result of the foregoing, Bellicum's public statements were materially false and misleading at all relevant times.     

On January 30, 2018, post-market, Bellicum issued a press release entitled "Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States," announcing that it had "received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501." 

On this news, Bellicum's share price fell $2.12, or 25.85%, to close at $6.08 on January 31, 2018.

Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

 

Primary Logo

Distribution channels: Consumer Goods, Law


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.